Giuseppe Giaccone
Impact in
- Oncology top 0.01%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 352
- Lung Cancer Research Studies 121
- Colorectal Cancer Treatments and Studies 61
- Cancer Treatment and Pharmacology 56
-
- Lung Cancer Treatments and Mutations 228
- Lung Cancer Diagnosis and Treatment 49
- Co-authors
- Frank A.E. Kruyt (31 shared papers)Herbert M. Pinedo (67 shared papers)José Antonio Rodríguez (36 shared papers)Jane B. Trepel (18 shared papers)Egbert F. Smit (47 shared papers)Len Neckers (5 shared papers)Pieter E. Postmus (34 shared papers)Linda E. Bröker (10 shared papers)
- Journals
- Journal of Clinical Oncology (137 papers)Annals of Oncology (62 papers)European Journal of Cancer (49 papers)Journal of Thoracic Oncology (43 papers)Lung Cancer (35 papers)
- Partner nations
- United StatesNetherlandsItaly
In The Last Decade
Giuseppe Giaccone
760 papers receiving 46.8k citations
Giuseppe Giaccone's Hit Papers
Peers
Comparison fields: 5 of 170
- Oncology 19.4k
- Pulmonary and Respiratory Medicine 17.9k
- Cancer Research 5.2k
- Neurology 3.2k
- Molecular Biology 15.0k
Countries citing papers authored by Giuseppe Giaccone
This map shows the geographic impact of Giuseppe Giaccone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuseppe Giaccone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuseppe Giaccone more than expected).
Fields of papers citing papers by Giuseppe Giaccone
This network shows the impact of papers produced by Giuseppe Giaccone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuseppe Giaccone. The network helps show where Giuseppe Giaccone may publish in the future.
Co-authors
The 25 scholars most cited alongside Giuseppe Giaccone, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 774 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2003 | 2456 |
| 2 | Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 Hit paper breakdown → | 2004 | 1435 |
| 3 | Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 Hit paper breakdown → | 2004 | 1421 |
| 4 | Targeting the dynamic HSP90 complex in cancer Hit paper breakdown → | 2010 | 1260 |
| 5 | Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Hit paper breakdown → | 2013 | 1005 |
| 6 | Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Hit paper breakdown → | 2010 | 946 |
| 7 | Cell Death Independent of Caspases: A Review Hit paper breakdown → | 2005 | 767 |
| 8 | American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer Hit paper breakdown → | 2009 | 760 |
| 9 | Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Hit paper breakdown → | 2015 | 708 |
| 10 | Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials Hit paper breakdown → | 2005 | 534 |
| 11 | Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer Hit paper breakdown → | 2007 | 495 |
| 12 | Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada Hit paper breakdown → | 2005 | 488 |
| 13 | Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Hit paper breakdown → | 2017 | 475 |
| 14 | A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. | 2002 | 446 |
| 15 | Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. Hit paper breakdown → | 1998 | 431 |
| 16 | American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy Hit paper breakdown → | 2011 | 406 |
| 17 | 1997 | 393 | |
| 18 | Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Hit paper breakdown → | 2013 | 383 |
| 19 | Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial Hit paper breakdown → | 2013 | 381 |
| 20 | Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Hit paper breakdown → | 2013 | 323 |
About Giuseppe Giaccone
Giuseppe Giaccone is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Neurology and Cancer Research, having authored 774 papers that have together received 48.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (228 papers), Lung Cancer Research Studies (121 papers), Cancer therapeutics and mechanisms (77 papers), Colorectal Cancer Treatments and Studies (61 papers), Myasthenia Gravis and Thymoma (58 papers), Cancer Treatment and Pharmacology (56 papers), Lung Cancer Diagnosis and Treatment (49 papers) and Cancer Genomics and Diagnostics (45 papers). The work is most often cited by research in Oncology (19.4k citations), Pulmonary and Respiratory Medicine (17.9k citations), Cancer Research (5.2k citations), Neurology (3.2k citations) and Molecular Biology (15.0k citations). Giuseppe Giaccone has collaborated with scholars based in United States, Netherlands and Italy. Frequent co-authors include Frank A.E. Kruyt, Herbert M. Pinedo, José Antonio Rodríguez, Jane B. Trepel, Egbert F. Smit, Len Neckers, Pieter E. Postmus, Linda E. Bröker, Mehdi Mollapour and Godefridus J. Peters. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Journal of Thoracic Oncology and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.